JP2019512498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512498A5 JP2019512498A5 JP2018548393A JP2018548393A JP2019512498A5 JP 2019512498 A5 JP2019512498 A5 JP 2019512498A5 JP 2018548393 A JP2018548393 A JP 2018548393A JP 2018548393 A JP2018548393 A JP 2018548393A JP 2019512498 A5 JP2019512498 A5 JP 2019512498A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense oligonucleotide
- pharmaceutical composition
- composition according
- conjugate
- oligonucleotide conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16160149 | 2016-03-14 | ||
| EP16160149.7 | 2016-03-14 | ||
| PCT/EP2017/055925 WO2017157899A1 (en) | 2016-03-14 | 2017-03-14 | Oligonucleotides for reduction of pd-l1 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020106728A Division JP7002603B2 (ja) | 2016-03-14 | 2020-06-22 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512498A JP2019512498A (ja) | 2019-05-16 |
| JP2019512498A5 true JP2019512498A5 (cg-RX-API-DMAC10.html) | 2020-04-16 |
| JP6748219B2 JP6748219B2 (ja) | 2020-08-26 |
Family
ID=58314191
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548393A Active JP6748219B2 (ja) | 2016-03-14 | 2017-03-14 | Ｐｄ−ｌ１発現低減用のオリゴヌクレオチド |
| JP2020106728A Active JP7002603B2 (ja) | 2016-03-14 | 2020-06-22 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
| JP2021212541A Active JP7447073B2 (ja) | 2016-03-14 | 2021-12-27 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
| JP2024000251A Active JP7791222B2 (ja) | 2016-03-14 | 2024-01-04 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
| JP2025245488A Pending JP2026075623A (ja) | 2016-03-14 | 2025-12-11 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020106728A Active JP7002603B2 (ja) | 2016-03-14 | 2020-06-22 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
| JP2021212541A Active JP7447073B2 (ja) | 2016-03-14 | 2021-12-27 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
| JP2024000251A Active JP7791222B2 (ja) | 2016-03-14 | 2024-01-04 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
| JP2025245488A Pending JP2026075623A (ja) | 2016-03-14 | 2025-12-11 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
Country Status (30)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0923225A2 (pt) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | metodo para sintese de acidos nucleicos modificados no atomo de fosforo |
| EP2451461A4 (en) | 2009-07-06 | 2013-05-29 | Ontorii Inc | NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| DK2872147T3 (da) | 2012-07-13 | 2023-02-20 | Wave Life Sciences Ltd | Fremgangsmåde til fremstilling af kirale oligonukleotider |
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| EP3094728B1 (en) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Chiral design |
| AU2015367378A1 (en) | 2014-12-17 | 2017-06-15 | Proqr Therapeutics Ii B.V. | Targeted RNA editing |
| BR112018001232A2 (pt) | 2015-07-21 | 2018-09-25 | The Children's Medical Center Corporation | pd-l1 que expressa células-tronco hematopoéticas e usos |
| CA3013683C (en) | 2016-03-14 | 2021-07-13 | F. Hoffmann-La Roche Ag | Oligonucleotides for reduction of pd-l1 expression |
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| US20220354888A1 (en) * | 2016-08-03 | 2022-11-10 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
| WO2018041973A1 (en) | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| KR102519171B1 (ko) | 2016-10-07 | 2023-04-07 | 세카나 파머씨티컬스 지엠비에이치 엔 씨오. 케이지 | 암 치료를 위한 새로운 접근법 |
| WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
| KR20200030594A (ko) * | 2017-10-16 | 2020-03-20 | 에프. 호프만-라 로슈 아게 | B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자 |
| EP3684377B1 (en) | 2017-10-20 | 2022-12-07 | Dicerna Pharmaceuticals, Inc. | Methods for treating hepatitis b infection |
| MY203356A (en) | 2018-01-12 | 2024-06-25 | Bristol Myers Squibb Co | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| WO2019140236A1 (en) * | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| CN112513273A (zh) | 2018-06-22 | 2021-03-16 | 豪夫迈·罗氏有限公司 | 用于调节scn9a表达的寡核苷酸 |
| WO2020007772A1 (en) * | 2018-07-02 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting gbp-1 |
| WO2020011653A1 (en) * | 2018-07-09 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting kynu |
| BR112021000538A2 (pt) | 2018-07-13 | 2021-04-06 | F. Hoffmann-La Roche Ag | Oligonucleotídeos para modular a expressão de rtel1 |
| WO2020081585A1 (en) * | 2018-10-15 | 2020-04-23 | The Brigham And Women's Hospital, Inc. | The long non-coding rna inca1 and homo sapiens heterogeneous nuclear ribonucleoprotein h1 (hnrnph1) as therapeutic targets for immunotherapy |
| WO2020178258A1 (en) * | 2019-03-05 | 2020-09-10 | F. Hoffmann-La Roche Ag | Intracellular targeting of molecules |
| US20220177894A1 (en) | 2019-04-02 | 2022-06-09 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for immunotherapy |
| EP3959313A4 (en) * | 2019-04-26 | 2023-09-27 | Stoke Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING OF ALTERNATIVE INTRONS |
| CN114051531A (zh) | 2019-05-03 | 2022-02-15 | 瑟卡尔纳制药有限公司 | 用于在肿瘤治疗中使用的pd-l1反义寡核苷酸 |
| WO2021122910A1 (en) * | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of sbds inhibitors for treating hepatitis b virus infection |
| JP7634542B2 (ja) * | 2019-12-19 | 2025-02-21 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用 |
| WO2021123086A1 (en) * | 2019-12-20 | 2021-06-24 | F. Hoffmann-La Roche Ag | Enhanced oligonucleotides for inhibiting scn9a expression |
| EP4081217A1 (en) * | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| WO2021173812A1 (en) * | 2020-02-28 | 2021-09-02 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
| JP2023536999A (ja) * | 2020-08-05 | 2023-08-30 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎患者のオリゴヌクレオチド処置 |
| CN114507663B (zh) * | 2020-11-16 | 2026-07-17 | 浙江柏拉阿图医药科技有限公司 | 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用 |
| TW202246500A (zh) * | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| CN115216474B (zh) * | 2021-04-15 | 2025-09-30 | 武汉大学 | 促进pd-l1外显子3跳跃的反义寡核苷酸及其应用 |
| CN117836006A (zh) * | 2021-08-04 | 2024-04-05 | 和博医药有限公司 | 用于递送治疗活性剂的配体缀合物 |
| CN113789324B (zh) * | 2021-08-17 | 2023-08-25 | 广东省大湾区华南理工大学聚集诱导发光高等研究院 | 一种aie探针及其制备方法与在荧光定量pcr方法中的应用 |
| AU2022384619A1 (en) | 2021-11-11 | 2024-04-11 | F. Hoffmann-La Roche Ag | Pharmaceutical combinations for treatment of hbv |
| EP4551596A4 (en) * | 2022-07-06 | 2026-07-22 | Adverum Biotechnologies Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACHROMOTOPSY |
| TW202430637A (zh) | 2022-11-16 | 2024-08-01 | 美商戴瑟納製藥股份有限公司 | Stat3靶向性寡核苷酸及其用途 |
| CN116597936A (zh) * | 2023-01-30 | 2023-08-15 | 溪砾科技(深圳)有限公司 | 一种识别mRNA非翻译区药物作用靶点的方法、装置及计算机可读存储介质 |
| TW202504619A (zh) * | 2023-07-20 | 2025-02-01 | 大陸商上海舶望製藥有限公司 | 用於抑制pd-l1表達的組合物和方法 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
| US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
| US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
| DE3738460A1 (de) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | Modifizierte oligonukleotide |
| US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
| US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
| RU2123528C1 (ru) * | 1990-11-08 | 1998-12-20 | Чирон Корпорейшн | Способ получения белков hcv, пригодных для использования в вакцине или иммуноанализе, асиалогликопротеин (варианты), композиция для использования в вакцине или в иммуноанализе (варианты), способ очистки асиалогликопротеина и способ понижения содержания или элиминации hcv |
| DE69132510T2 (de) | 1990-11-08 | 2001-05-03 | Hybridon, Inc. | Verbindung von mehrfachreportergruppen auf synthetischen oligonukleotiden |
| JP2823959B2 (ja) | 1991-10-24 | 1998-11-11 | アイシス・ファーマシューティカルス・インコーポレーテッド | 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド |
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
| EP0804456B1 (en) | 1994-10-06 | 2002-08-21 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid conjugates |
| US5684142A (en) | 1995-06-07 | 1997-11-04 | Oncor, Inc. | Modified nucleotides for nucleic acid labeling |
| TW520293B (en) | 1995-11-22 | 2003-02-11 | Univ Johns Hopkins Med | Delivery system to enhance cellular uptake of biomolecules |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US5770716A (en) | 1997-04-10 | 1998-06-23 | The Perkin-Elmer Corporation | Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same |
| ES2210761T3 (es) | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
| EP1015469B2 (en) | 1997-09-12 | 2015-11-18 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
| US6096875A (en) | 1998-05-29 | 2000-08-01 | The Perlein-Elmer Corporation | Nucleotide compounds including a rigid linker |
| US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
| US6335432B1 (en) | 1998-08-07 | 2002-01-01 | Bio-Red Laboratories, Inc. | Structural analogs of amine bases and nucleosides |
| US6335437B1 (en) | 1998-09-07 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Methods for the preparation of conjugated oligomers |
| BRPI0008131B8 (pt) | 1999-02-12 | 2021-05-25 | Daiichi Sankyo Co Ltd | composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno |
| ATE356824T1 (de) | 1999-05-04 | 2007-04-15 | Santaris Pharma As | L-ribo-lna analoge |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| WO2005007855A2 (en) | 2003-07-14 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF B7-H1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20060276422A1 (en) | 2001-05-18 | 2006-12-07 | Nassim Usman | RNA interference mediated inhibition of B7-H1 gene expression using short interfering nucleic acid (siNA) |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| DE60334303D1 (de) * | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| EP2284269B1 (en) | 2002-11-18 | 2017-08-09 | Roche Innovation Center Copenhagen A/S | Antisense design |
| DK2270162T3 (en) | 2003-06-12 | 2019-01-21 | Alnylam Pharmaceuticals Inc | PRESERVED HBV AND HCV SEQUENCES USED FOR GEN-SILENCING |
| ES2302898T3 (es) | 2003-07-11 | 2008-08-01 | Lbr Medbiotech B.V. | Transferencia de genes a celulas musculares mediada por el receptor de manosa-6-fosfato. |
| CN101084438B (zh) * | 2004-10-06 | 2013-12-25 | 梅约医学教育与研究基金会 | B7-h1和癌症的诊断、预后和治疗方法 |
| PL1810026T3 (pl) | 2004-10-06 | 2018-08-31 | Mayo Foundation For Medical Education And Research | B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego |
| US20120122801A1 (en) | 2005-01-05 | 2012-05-17 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
| DK1907000T4 (da) | 2005-06-08 | 2020-03-30 | The President And Fellows Of Harvard College | Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1). |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| DE602007009487D1 (de) | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-modifizierte bicyclische nukleinsäureanaloga |
| EP2505646A1 (en) | 2006-05-05 | 2012-10-03 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of CRP |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| CA2673870A1 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
| DK2170917T3 (da) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro |
| WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
| US9290534B2 (en) | 2008-04-04 | 2016-03-22 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside |
| US8575123B2 (en) | 2008-04-11 | 2013-11-05 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| MX2011005691A (es) | 2008-11-28 | 2011-07-20 | Univ Emory | Metodos para el tratamiento de infecciones y tumores. |
| MX356367B (es) * | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| CN107090437A (zh) | 2009-03-06 | 2017-08-25 | 国立大学法人三重大学 | 用于增强t细胞功能的方法 |
| CN102459596B (zh) * | 2009-05-06 | 2016-09-07 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
| KR101704988B1 (ko) * | 2009-05-28 | 2017-02-08 | 큐알엔에이, 인크. | 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료 |
| EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| EP3578657B1 (en) * | 2010-04-06 | 2024-03-20 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of cd274/pd-l1 gene |
| US8765708B2 (en) * | 2010-05-18 | 2014-07-01 | Kevin Petrecca | Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas |
| US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| RU2745848C2 (ru) | 2010-08-17 | 2021-04-01 | Сирна Терапьютикс, Инк. | ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
| ES2730393T3 (es) | 2010-10-28 | 2019-11-11 | Benitec Biopharma Ltd | Tratamiento contra el VHB |
| RU2013117288A (ru) | 2010-12-17 | 2015-01-27 | Эрроухэд Рисерч Корпорейшн | СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА |
| RU2582235C2 (ru) | 2010-12-29 | 2016-04-20 | Ф.Хоффманн-Ля Рош Аг | Низкомолекулярные конъюгаты для внутриклеточной доставки нуклеиновых кислот |
| SI3505528T1 (sl) | 2011-04-21 | 2021-04-30 | Glaxo Group Limited | Modulacija izražanja virusa hepatitisa B (HBV) |
| PT2726613T (pt) | 2011-06-30 | 2018-10-26 | Arrowhead Pharmaceuticals Inc | Composições e métodos para inibição da expressão de genes do vírus da hepatite b |
| CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| US10023861B2 (en) | 2011-08-29 | 2018-07-17 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| EP2753631A1 (en) | 2011-09-07 | 2014-07-16 | Marina Biotech, Inc. | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers |
| WO2013049307A2 (en) | 2011-09-30 | 2013-04-04 | University Of Miami | Enhanced immune memory development by aptamer targeted mtor inhibition of t cells |
| ES2918580T3 (es) * | 2011-10-17 | 2022-07-19 | Io Biotech Aps | Inmunoterapia basada en PD-L1 |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| JP2016528873A (ja) | 2012-05-16 | 2016-09-23 | ラナ セラピューティクス インコーポレイテッド | 遺伝子発現を調節するための組成物及び方法 |
| EA201492120A1 (ru) * | 2012-05-16 | 2015-10-30 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии atp2a2 |
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| RU2692773C2 (ru) | 2012-11-30 | 2019-06-27 | Ф.Хоффманн-Ля Рош Аг | Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1 |
| CA2893801A1 (en) * | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| WO2014118272A1 (en) * | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| MX367083B (es) | 2013-06-27 | 2019-08-05 | Roche Innovation Ct Copenhagen As | Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9). |
| WO2015114146A1 (en) * | 2014-02-03 | 2015-08-06 | Sividon Diagnostics Gmbh | Method for predicting the response to an anti-her2 containing therapy and/or chemotherapy in patients with breast cancer |
| WO2016025647A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| AU2015329974B2 (en) | 2014-10-10 | 2019-06-20 | F. Hoffmann-La Roche Ag | GaINAc phosphoramidites, nucleic acid conjugates thereof and their use |
| WO2016138278A2 (en) | 2015-02-27 | 2016-09-01 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting checkpoint gene expression and uses thereof |
| GB201507926D0 (en) * | 2015-05-08 | 2015-06-24 | Proqr Therapeutics N V | Improved treatments using oligonucleotides |
| WO2017055423A1 (en) * | 2015-10-02 | 2017-04-06 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugation process |
| WO2017084987A1 (en) | 2015-11-16 | 2017-05-26 | F. Hoffmann-La Roche Ag | GalNAc CLUSTER PHOSPHORAMIDITE |
| WO2017100587A1 (en) | 2015-12-09 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting programmed cell death 1 ligand 1 (pd-l1) and methods of use thereof |
| CA3013683C (en) | 2016-03-14 | 2021-07-13 | F. Hoffmann-La Roche Ag | Oligonucleotides for reduction of pd-l1 expression |
| WO2018215049A1 (en) | 2017-05-23 | 2018-11-29 | F. Hoffmann-La Roche Ag | Process for galnac oligonucleotide conjugates |
-
2017
- 2017-03-14 CA CA3013683A patent/CA3013683C/en active Active
- 2017-03-14 CN CN201780017220.7A patent/CN108779465B/zh active Active
- 2017-03-14 PE PE2022000852A patent/PE20230157A1/es unknown
- 2017-03-14 CA CA3120687A patent/CA3120687A1/en active Pending
- 2017-03-14 PE PE2020000807A patent/PE20201499A1/es unknown
- 2017-03-14 KR KR1020187026546A patent/KR102306797B1/ko active Active
- 2017-03-14 TW TW111134997A patent/TWI840950B/zh active
- 2017-03-14 CN CN202210443059.2A patent/CN114736901B/zh active Active
- 2017-03-14 CN CN202111366505.6A patent/CN114085836B/zh active Active
- 2017-03-14 CN CN202210442730.1A patent/CN114736900B/zh active Active
- 2017-03-14 RS RS20210240A patent/RS61528B1/sr unknown
- 2017-03-14 CN CN202210440723.8A patent/CN114717235A/zh active Pending
- 2017-03-14 JP JP2018548393A patent/JP6748219B2/ja active Active
- 2017-03-14 UA UAA201810179A patent/UA127432C2/uk unknown
- 2017-03-14 TW TW106108305A patent/TWI721128B/zh active
- 2017-03-14 ES ES17710874T patent/ES2857702T3/es active Active
- 2017-03-14 HU HUE17710874A patent/HUE053172T2/hu unknown
- 2017-03-14 RU RU2018134379A patent/RU2747822C2/ru active
- 2017-03-14 HR HRP20210315TT patent/HRP20210315T1/hr unknown
- 2017-03-14 TW TW113111556A patent/TW202428874A/zh unknown
- 2017-03-14 TW TW109135755A patent/TWI790485B/zh active
- 2017-03-14 IL IL296483A patent/IL296483B2/en unknown
- 2017-03-14 WO PCT/EP2017/055925 patent/WO2017157899A1/en not_active Ceased
- 2017-03-14 KR KR1020217030513A patent/KR102417646B1/ko active Active
- 2017-03-14 PL PL17710874T patent/PL3430141T3/pl unknown
- 2017-03-14 US US15/458,800 patent/US20170283496A1/en not_active Abandoned
- 2017-03-14 CR CR20180432A patent/CR20180432A/es unknown
- 2017-03-14 IL IL303077A patent/IL303077B2/en unknown
- 2017-03-14 TW TW109135754A patent/TWI794662B/zh active
- 2017-03-14 KR KR1020237031671A patent/KR102805002B1/ko active Active
- 2017-03-14 SI SI201730645T patent/SI3430141T1/sl unknown
- 2017-03-14 CR CR20200119A patent/CR20200119A/es unknown
- 2017-03-14 EP EP17710874.3A patent/EP3430141B1/en active Active
- 2017-03-14 PT PT177108743T patent/PT3430141T/pt unknown
- 2017-03-14 EP EP20201780.2A patent/EP3786297A1/en active Pending
- 2017-03-14 PE PE2018001567A patent/PE20181892A1/es unknown
- 2017-03-14 KR KR1020227022628A patent/KR102580776B1/ko active Active
- 2017-03-14 MX MX2018010830A patent/MX2018010830A/es unknown
- 2017-03-14 IL IL317818A patent/IL317818A/en unknown
- 2017-03-14 AR ARP170100626A patent/AR108038A1/es unknown
- 2017-03-14 DK DK17710874.3T patent/DK3430141T3/da active
- 2017-03-14 LT LTEP17710874.3T patent/LT3430141T/lt unknown
- 2017-03-14 SG SG11201807854SA patent/SG11201807854SA/en unknown
- 2017-03-14 KR KR1020257014623A patent/KR20250065735A/ko active Pending
- 2017-03-14 AU AU2017235278A patent/AU2017235278C1/en active Active
- 2017-03-14 MY MYPI2018703228A patent/MY194912A/en unknown
-
2018
- 2018-07-24 IL IL260759A patent/IL260759B/en unknown
- 2018-07-26 CO CONC2018/0007761A patent/CO2018007761A2/es unknown
- 2018-09-07 MX MX2022012221A patent/MX2022012221A/es unknown
- 2018-09-07 CL CL2018002570A patent/CL2018002570A1/es unknown
- 2018-09-12 PH PH12018501964A patent/PH12018501964A1/en unknown
-
2019
- 2019-10-25 US US16/664,749 patent/US10745480B2/en active Active
-
2020
- 2020-03-31 CL CL2020000865A patent/CL2020000865A1/es unknown
- 2020-04-02 US US16/839,025 patent/US10829555B2/en active Active
- 2020-04-17 AR ARP200101090A patent/AR118719A2/es unknown
- 2020-04-28 CL CL2020001126A patent/CL2020001126A1/es unknown
- 2020-04-28 CL CL2020001127A patent/CL2020001127A1/es unknown
- 2020-06-22 JP JP2020106728A patent/JP7002603B2/ja active Active
- 2020-08-21 US US17/000,203 patent/US11466081B2/en active Active
-
2021
- 2021-09-20 AU AU2021236439A patent/AU2021236439B2/en active Active
- 2021-12-27 JP JP2021212541A patent/JP7447073B2/ja active Active
-
2022
- 2022-02-01 IL IL290294A patent/IL290294B2/en unknown
- 2022-04-13 AU AU2022202479A patent/AU2022202479B2/en active Active
- 2022-10-07 US US18/045,109 patent/US12552862B2/en active Active
-
2024
- 2024-01-04 JP JP2024000251A patent/JP7791222B2/ja active Active
- 2024-05-29 AU AU2024203581A patent/AU2024203581B2/en active Active
-
2025
- 2025-12-11 JP JP2025245488A patent/JP2026075623A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021072862A5 (cg-RX-API-DMAC10.html) | ||
| IL317818A (en) | Oligonucleotides to reduce PD-L1 expression | |
| Martinsen et al. | The use of toll-like receptor agonists in HIV-1 cure strategies | |
| JP2020022483A5 (cg-RX-API-DMAC10.html) | ||
| JP2017505623A5 (cg-RX-API-DMAC10.html) | ||
| US9943604B2 (en) | Targeted therapeutic nucleosides and their use | |
| JP6649248B2 (ja) | 細胞取り込みの向上のための化合物および方法 | |
| KR102627418B1 (ko) | 변형된 올리고뉴클레오티드 및 사용 방법 | |
| KR102214740B1 (ko) | Mir-122를 조정하기 위한 마이크로rna 화합물 및 방법 | |
| US20200270609A1 (en) | Single-Stranded RNAI Oligonucleotides Targeting APOC-III | |
| IL300119A (en) | Oligonucleotides to induce paternal UBE3A expression | |
| HRP20250408T1 (hr) | Kojugati i njihova priprema i uporaba | |
| JP2018523668A5 (cg-RX-API-DMAC10.html) | ||
| JP2019531763A5 (cg-RX-API-DMAC10.html) | ||
| HRP20250974T1 (hr) | Oligomeri i oligomerni konjugati | |
| CN102066444A (zh) | 胶束装配体 | |
| RS62523B1 (sr) | Kompozicije i postupci za inhibiciju genske ekspresije lpa | |
| JP2010532168A5 (cg-RX-API-DMAC10.html) | ||
| JP2017536366A5 (cg-RX-API-DMAC10.html) | ||
| RU2017139121A (ru) | Композиции для модулирования экспрессии c9orf72 | |
| JP2017513469A5 (cg-RX-API-DMAC10.html) | ||
| WO2011062965A2 (en) | Targeting monomers and polymers having targeting blocks | |
| TW201639962A (zh) | Ｒｎａ干擾劑 | |
| JP2009524696A5 (cg-RX-API-DMAC10.html) | ||
| CN102065902A (zh) | 聚合物载体 |